Literature DB >> 19880497

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Hartmut Döhner1, Elihu H Estey, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Alan K Burnett, Hervé Dombret, Pierre Fenaux, David Grimwade, Richard A Larson, Francesco Lo-Coco, Tomoki Naoe, Dietger Niederwieser, Gert J Ossenkoppele, Miguel A Sanz, Jorge Sierra, Martin S Tallman, Bob Löwenberg, Clara D Bloomfield.   

Abstract

In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

Entities:  

Mesh:

Year:  2009        PMID: 19880497     DOI: 10.1182/blood-2009-07-235358

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  1170 in total

1.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

Authors:  Vikas Gupta; Martin S Tallman; Wensheng He; Brent R Logan; Edward Copelan; Robert Peter Gale; Hanna J Khoury; Thomas Klumpp; John Koreth; Hillard M Lazarus; David I Marks; Rodrigo Martino; David A Rizzieri; Jacob M Rowe; Mitchell Sabloff; Edmund K Waller; John F DiPersio; Donald W Bunjes; Daniel J Weisdorf
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

3.  Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation.

Authors:  Martin David Berger; Bernhard Gerber; Kornelius Arn; Oliver Senn; Urs Schanz; Georg Stussi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

4.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 5.  Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Authors:  Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-08-30       Impact factor: 3.156

6.  Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Authors:  Zejuan Li; Tobias Herold; Chunjiang He; Peter J M Valk; Ping Chen; Vindi Jurinovic; Ulrich Mansmann; Michael D Radmacher; Kati S Maharry; Miao Sun; Xinan Yang; Hao Huang; Xi Jiang; Maria-Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann; Abdel Elkahloun; Mary Beth Neilly; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Konstanze Döhner; Lars Bullinger; Paul P Liu; Ruud Delwel; Guido Marcucci; Bob Lowenberg; Clara D Bloomfield; Janet D Rowley; Stefan K Bohlander; Jianjun Chen
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

7.  Clinical Features and Outcomes of 666 Cases with Therapy-Related Myelodysplastic Syndrome (t-MDS).

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-06       Impact factor: 0.900

8.  Expression and clinical significance of SNAI1 and ZEB1 genes in acute myeloid leukemia patients.

Authors:  Wafaa Ghoneim Shousha; Shimaa Shawki Ramadan; Abeer Salah El-Saiid; Ahmed Essmat Abdelmoneim; Marwa Ahmed Abbas
Journal:  Mol Biol Rep       Date:  2019-05-04       Impact factor: 2.316

Review 9.  Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

Authors:  Abraham S Kanate; Marcelo C Pasquini; Parameswaran N Hari; Mehdi Hamadani
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

10.  The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.

Authors:  Martin Culen; Zdenka Kosarova; Ivana Jeziskova; Adam Folta; Jana Chovancova; Tomas Loja; Nikola Tom; Vojtech Bystry; Veronika Janeckova; Dana Dvorakova; Jiri Mayer; Zdenek Racil
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.